4.5 Review

Hypoxia-inducible factor-1: a promising therapeutic target for autoimmune diseases

Journal

EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 21, Issue 7, Pages 715-723

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/14728222.2017.1336539

Keywords

Autoimmune diseases; hypoxia-inducible factor-1; inflammation; therapeutic target

Funding

  1. National Natural Science Foundation of China [81573222, 81373073, 81671611]

Ask authors/readers for more resources

Introduction: Hypoxia-inducible factor-1 (HIF-1) plays a crucial role in both innate and adaptive immunity. Emerging evidence indicates that HIF-1 is associated with the inflammation and pathologic activities of autoimmune diseases.Areas covered: Considering that the types of autoimmune diseases are complicated and various, this review aims to cover the typical kinds of autoimmune diseases, discuss the molecular mechanisms, biological functions and expression of HIF-1 in these diseases, and further explore its therapeutic potential.Expert opinion: Inflammation and hypoxia are interdependent. HIF-1 as a key regulator of hypoxia, exerts a crucial role in the balance between Th17 and Treg, and involves in the inflammation and pathologic activities of autoimmune diseases. Although there are many challenges remaining to be overcome, targeting HIF-1 could be a promising strategy for autoimmune diseases therapies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available